OssDsign explores the conditions to carry out a directed share issue and announces an updated strategy and revised financial targets
June 3, 2025, 17:31 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) intends to explore the conditions to carry out a directed share issue corresponding to approximately nine million shares through an accelerated bookbuilding procedure to Swedish and international institutional investors (the “Directed Issue”), starting immediately. OssDsign has engaged DNB Carnegie Investment Bank AB (“DNB Carnegie”) to act as Sole Bookrunner in connection with the Directed Issue. In connection with the Directed Share issue, OssDsign announces an updated strategy, “ScaleToProfit”, together with revised financial targets for the strategy period 2025-2028 (“the Strategy Period”).
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE.
Strategy update and revised financial targets
Since announcing its strategy shift in September 2023 to become a pure play orthobiologics company, OssDsign has focused solely on the commercialization of OssDsign Catalyst in the U.S., which represents more than 70 percent of the global market for spinal bone grafts and is characterized by large volumes and highly attractive pricing. This strategy has been highly successful, with sales reaching SEK 134 million in 2024 and with gross margins above 95 percent for the financial year. OssDsign has seen the strong financial momentum continue into 2025, with the Q1 results showing continued robust growth of 65 percent, a gross margin of 96.4 percent and the best operating result in the history of the Company. The financial momentum has been accompanied by additional clinical and pre-clinical progress through a total of ten new publications since the beginning of 2024. This type of evidence continues to be a key pillar in OssDsign’s commercialization. To capitalize on this success, the Company’s updated strategy, “ScaleToProfit”, for the Strategy Period will include investments in four main areas:
- Sales and marketing
– Double US sales force by 2026 and accelerate marketing
- Research and development
– Launch two new products during the Strategy Period and obtain a minimum of one expanded indication clearance in the U.S.
- Clinical studies
– Continue building the PROPEL spinal fusion registry and conduct 2-3 smaller clinical prospective studies
- Production
– Implement a scalable and more cost-efficient production process and move to a predominant U.S. footprint
To reflect this strategy and provided that the Directed Issue is carried out successfully, the board of directors of the Company has resolved on revised financial targets:
– Deliver sales of more than SEK 400 million by 2028 – equivalent to over 30 percent compounded annual growth rate during the Strategy Period
– Become EBIT profitable and cash flow positive in the second half of Strategy Period
As such, if the Directed Issue is successful, the Company expects to be fully capitalized until cash flow positive and in a favourable position to capture additional long-term potential as (i) more than 90 percent of the spine Orthobiologics market remains untapped despite the strong market access and commercialization to date, and (ii) OssDsign Catalyst already has clearance for use in adjacent segments such as extremities, pelvis and trauma.
The Directed Issue
The subscription price and the number of new shares in the Directed Issue will be determined through an accelerated bookbuilding procedure, which will commence immediately following the publication of this press release and will be led by DNB Carnegie. Closing of the accelerated bookbuilding procedure, pricing and allocation of the new shares are expected to take place before the commencement of trading on Nasdaq First North Growth Market at 09:00 CEST on 4 June 2025. The timing of closing, pricing and allocation in the bookbuilding procedure are determined at the discretion of the Company and may be shortened, extended or cancelled at any time, meaning the Company may refrain, in part or in full, from carrying out the Directed Issue. The Company will announce the outcome of the Directed Issue in a press release after the bookbuilding procedure has been completed. The net proceeds from the Directed Issue are intended to be used for:
– Sales force expansion and marketing acceleration
– Research and development
– Clinical studies and programs
– Production scalability and U.S. footprint
– Quality assurance, back office and other corporate purposes
Prior to the Directed Issue, the Company's board of directors has made an overall assessment and carefully considered the possibility to raise capital through a rights issue with preferential right for the Company's existing shareholders. The board of directors considers that the reasons for deviating from the shareholders’ preferential right are (i) that a rights issue would take a longer time to complete and entail a higher risk for an adverse effect on the share price, particularly in light of the current market volatility and the challenging market conditions, (ii) to diversify and strengthen the Company's shareholder base with institutional investors, (iii) that to carry out a directed share issue can be made at lower costs and with less complexity than a rights issue and in light of the current market conditions, the board of directors has assessed that a rights issue would also require external underwriting from a guarantor syndicate that would entail additional significant costs. Considering the above, the board of directors has made the assessment that a directed share issue with deviation from the shareholders’ preferential right is the most favourable alternative for OssDsign to finance the announced updated strategy, creates value for the Company and is in the best interest of the Company’s shareholders. The board of directors thus considers that the reasons outweigh the main rule that new share issues are to be carried out with preferential rights for the shareholders.
Since the subscription price in the Directed Issue will be determined through an accelerated bookbuilding procedure, the board of directors considers the subscription price to reflect market terms and conditions.
As OssDsign is deemed to carry out protection-worthy activities under the Screening of Foreign Direct Investments Act (Sw. lagen (2023:560) om granskning av utländska direktinvesteringar), certain investments in the Directed Issue may need to be notified to the Inspectorate for Strategic Products (ISP), in which case investors must obtain a decision from the ISP approving the notification or leaving the notification without action before the investment can be carried out.
In connection with the Directed Issue, the Company will undertake, subject to customary exceptions, not to issue additional shares for a period of 90 calendar days after the settlement date of the Directed Issue. In addition, OssDsign’s board members and members of the senior management will undertake not to divest any shares in OssDsign for a period of 180 days from the settlement date of the Directed Issue, subject to customary exceptions, including that divestments may be made of such number of shares as awarded under the Company’s 2022/2025 incentive programs. The next exercise period for the 2022/2025 incentive programs lasts 1 July–31 December 2025 and entitles the participants to subscription of up to 1,466,993 new shares.
Advisors
DNB Carnegie acts as Sole Bookrunner and Setterwalls Advokatbyrå AB acts as legal counsel to the Company in connection with the Directed Issue.
For more information, please contact:
Morten Henneveld, CEO
Phone: + 46(0)73 382 43 90
E-mail: [email protected]
Anders Svensson, CFO
Phone: + 46(0)70 272 96 40
E-mail: [email protected]
This information is such that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 3 June 2025, at 17:31 CEST.
About OssDsign
OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. The company has a strong presence in the U.S. market. OssDsign's share is traded on Nasdaq First North Growth Market in Stockholm, Sweden. DNB Carnegie is the Company’s Certified Adviser.
IMPORTANT INFORMATION
Publication, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction.
This press release is not a prospectus for the purposes of Regulation (EG) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. The Company has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Directed Issue. In any EEA member state, this communication is only addressed to and is only directed at “qualified investors” in that member state within the meaning of the Prospectus Regulation.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Canada, Hong Kong, Japan, Singapore, South Africa or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” (according to the definition set forth in Section 86(7) of the United Kingdom Financial Services and Markets Act 2000) who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.
DNB Carnegie is acting for the Company in connection with the transaction and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the transaction or any other matter referred to herein.
This press release does not constitute a recommendation concerning any investor’s decision regarding the Directed Issue. Each investor or potential investor should conduct his, her or its own investigation, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities can decrease as well as increase. Achieved results do not provide guidance for future results.
Forward-looking statements
This press release contains forward-looking statements that reflect the Company’s intentions, assessments, or current expectations about and targets for the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this press release. Readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertakes to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release.
Information to distributors
Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the “MiFID II Product Governance Requirements”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer” (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the current shares in the Company have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the “Target Market Assessment”). Notwithstanding the Target Market Assessment, distributors should note that: the price of the shares in the Company may decline and investors could lose all or part of their investment; the shares in the Company offer no guaranteed income and no capital protection; and an investment in the shares in the Company is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Directed Issue.
For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in the Company.
Each distributor is responsible for undertaking its own target market assessment in respect of the shares in the Company and determining appropriate distribution channels.
This is a translation of the Swedish version of the press release. In case of discrepancies, the Swedish wording shall prevail.